Kewaunee Scientific (KEQU) CFO sells 2,000 shares at ~$37.57 average

Rhea-AI Filing Summary

Kewaunee Scientific Corporation Chief Financial Officer Donald T. Gardner III reported an open-market sale of 2,000 shares of common stock on January 6, 2026. The shares were sold at a weighted average price of $37.57, with individual trade prices ranging from $37.50 to $38.00.

Following this transaction, Gardner beneficially owned 9,564 shares of Kewaunee Scientific common stock in direct ownership. He has undertaken to provide, upon request, detailed information about the number of shares sold at each separate price within the reported range.

Insider Trade Summary

Net Seller: 2,000 shares

Net Sell 1 txn

Insider Gardner Donald T. III

Role Chief Financial Officer

Sold 2,000 shs ($75K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,000	$37.57	$75K

Holdings After Transaction: Common Stock — 9,564 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $38.00 inclusive. The reporting person undertakes to provide Kewaunee Scientific Corporation ("Kewaunee"), any security holder of Kewaunee, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/07/2026 - 03:59 PM Learn about SEC filing dates

FAQ

What insider transaction did KEQU report in this Form 4?

The filing reports that Chief Financial Officer Donald T. Gardner III sold 2,000 shares of Kewaunee Scientific common stock on January 6, 2026.

At what price did the Kewaunee Scientific (KEQU) CFO sell shares?

The shares were sold at a weighted average price of $37.57 per share, with individual trades executed between $37.50 and $38.00 inclusive.

How many KEQU shares does the CFO own after this transaction?

After the reported sale, Donald T. Gardner III beneficially owned 9,564 shares of Kewaunee Scientific common stock in direct ownership.

What type of security was involved in this KEQU insider transaction?

The transaction involved common stock of Kewaunee Scientific Corporation. No derivative securities were reported in this filing.

Was the KEQU CFO’s share sale executed in a single trade or multiple trades?

The filing states that the sale was completed in multiple transactions at prices ranging from $37.50 to $38.00, resulting in a weighted average price of $37.57.

Can investors get detailed pricing for each KEQU trade in this insider sale?

Yes. The reporting person has agreed to provide Kewaunee Scientific, any of its security holders, or SEC staff, upon request, with full details on the number of shares sold at each separate price within the stated range.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gardner Donald T. III

(Last) (First) (Middle)

2700 WEST FRONT STREET

(Street)

STATESVILLE NC 28677

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KEWAUNEE SCIENTIFIC CORP /DE/ [ KEQU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S		2,000	D	$37.57(1)	9,564	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $38.00 inclusive. The reporting person undertakes to provide Kewaunee Scientific Corporation ("Kewaunee"), any security holder of Kewaunee, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Donald T. Gardner III	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.